Platform & Pipeline

We are currently developing the Gradalis immunotherapy in a number of advanced cancer indications, including:

Program
Preclinical
IND
Phase I
Phase II
Phase III
Gradalis Immunotherapy Platform
Vigil® Ewing's Sarcoma
Vigil® Advanced Ovarian
Vigil® + PD-1/PD-L1 Multiple cancers
Vigil® Solid tumors
Gradalis® Development Pipeline